Evidence map›Paper›PMID 41772734›Full record

ArticleActa neuropathologica communications2026

Pyroxd1 is essential for murine viability with the homozygous N155S recurrent variant linked to myopathy, muscle hypotrophy and osteopenia.

Frances J Evesson, Gregory Dziaduch, Joe Yasa, Heather A Best, Leonit Kiriaev, Ignatius Pang, Vanessa Jones, Emma Kettle, Katharine Zhang, Ann-Katrin Piper and 10 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Frances J EvessonSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. frances.evesson@sydney.edu.au.
Gregory Dziaduch *Kids Neuroscience Centre, The Children's Hospital at Westmead, Sydney, Australia.
Joe Yasa *Kids Neuroscience Centre, The Children's Hospital at Westmead, Sydney, Australia.
Heather A Best *Kids Neuroscience Centre, The Children's Hospital at Westmead, Sydney, Australia.
Leonit Kiriaev *Muscle Research, Murdoch Children's Research Institute, Melbourne, Australia.
Ignatius Pang *Children's Medical Research Institute, Westmead, Sydney, Australia.
Vanessa JonesChildren's Medical Research Institute, Westmead, Sydney, Australia.
Emma KettleWestmead Research Hub Electron Microscope Core Facility, The Westmead Institute for Medical Research, Sydney, Australia.
Katharine ZhangSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Ann-Katrin PiperKids Neuroscience Centre, The Children's Hospital at Westmead, Sydney, Australia.
Jesse R WarkChildren's Medical Research Institute, Westmead, Sydney, Australia.
Isaac ScottTexas Tech University Health Sciences Center, Lubbock, TX, USA.
Himanshu JoshiKids Neuroscience Centre, The Children's Hospital at Westmead, Sydney, Australia.
R Bryan SuttonTexas Tech University Health Sciences Center, Lubbock, TX, USA.
Patrick P L TamSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Peter J HouwelingMuscle Research, Murdoch Children's Research Institute, Melbourne, Australia.
Mark E GrahamChildren's Medical Research Institute, Westmead, Sydney, Australia.
Michaela YuenSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Frances A LemcketKids Neuroscience Centre, The Children's Hospital at Westmead, Sydney, Australia.
Sandra T CooperSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

Funding

National Health and Medical Research Council APP1143901National Health and Medical Research Council GNT1121651
6 · The paper itself

Abstract

Biallelic variants in PYROXD1 are associated with a life limiting muscle and connective tissue disorder characterised by generalised muscle weakness, breathing and feeding difficulties, distal laxity, hypernasal speech, blue sclera and osteopenia. PYROXD1 encodes an oxidoreductase implicated in mitochondrial function and tRNA ligase activity. Herein we present the first comprehensive suite of mouse models designed to elucidate PYROXD1 redox functions and the underlying pathogenetic basis for PYROXD1 disorders. A LacZ reporter strain reveals ubiquitous expression of Pyroxd1, particularly in the developing head, eye, heart and skin. Complete knockout (KO) of Pyroxd1 resulted in embryonic lethality between ED4.5–E9.5, suggesting Pyroxd1 performs a unique function during embryogenesis that cannot be substituted by other redox enzymes. Skeletal muscle tissue-specific KO, or stage-specific tamoxifen-induced KO during gestation or post-weaning, were viable but not sustainable models. Tamoxifen-inducible KO cell lines derived from these models provide valuable tools for dissecting Pyroxd1 function. Homozygous mice harbouring the recurrent human variant NM_024854.5:c.464A > G;p.(N155S), termed Pyroxd1N155S, phenocopied a severe PYROXD1 disorder, presenting from ~ 10 weeks of age with a progressive myopathy, myofibrillar disorganisation, decreased contractile strength, muscle hypotrophy and osteopenia. Conversely, homozygous Pyroxd1N155G mice, created incidentally during CRISPR editing, were phenotypically normal and provide an important benign control. Proteomic analyses reveal distinct molecular signatures between acute Pyroxd1 KO and Pyroxd1N155S models, highlighting differential effects of complete loss-of-function (KO) compared to partial enzymatic activity (N155S). Pyroxd1 activity is critical for numerous cell essential processes, including protein biosynthesis and turnover, tRNA ligase complex activity and the unfolded protein response, mitochondrial respiratory chain function (especially complex 1), with an implicated broader role in the exon-ligation step of pre-mRNA splicing. Together, these murine Pyroxd1 models establish an enabling platform for gaining mechanistic insight and guiding the path of future therapeutic development for PYROXD1 disorders.

Indexed as

Bone Diseases, MetabolicMuscular DiseasesOxidoreductasesAnimalsDisease Models, AnimalFemaleHomozygoteHumansMiceMice, Inbred C57BLMice, KnockoutMuscle, SkeletalOxidoreductases

Identifiers

PMID41772734
PMCPMC13059403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.